1. Home
  2. CHH vs APLS Comparison

CHH vs APLS Comparison

Compare CHH & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Choice Hotels International Inc.

CHH

Choice Hotels International Inc.

HOLD

Current Price

$116.84

Market Cap

4.4B

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$40.85

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHH
APLS
Founded
1939
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.2B
IPO Year
1997
2015

Fundamental Metrics

Financial Performance
Metric
CHH
APLS
Price
$116.84
$40.85
Analyst Decision
Hold
Hold
Analyst Count
11
21
Target Price
$109.70
$32.71
AVG Volume (30 Days)
474.9K
8.2M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.98%
N/A
EPS Growth
27.42
112.50
EPS
7.90
0.20
Revenue
$1,596,793,000.00
$1,003,782,000.00
Revenue This Year
$66.74
N/A
Revenue Next Year
$0.37
$18.19
P/E Ratio
$14.82
$204.28
Revenue Growth
0.75
28.46
52 Week Low
$84.04
$16.10
52 Week High
$136.45
$40.88

Technical Indicators

Market Signals
Indicator
CHH
APLS
Relative Strength Index (RSI) 71.58 87.65
Support Level $92.66 $18.53
Resistance Level $136.17 N/A
Average True Range (ATR) 3.49 0.23
MACD 1.77 0.99
Stochastic Oscillator 88.12 99.90

Price Performance

Historical Comparison
CHH
APLS

About CHH Choice Hotels International Inc.

At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Share on Social Networks: